两部门：鼓励商业健康保险扩大创新药投资规模

Group 1 - The core viewpoint of the article is the issuance of measures by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs, particularly encouraging commercial health insurance to expand investment in innovative drugs [1] Group 2 - The measures encourage commercial health insurance companies to provide stable and long-term investment for innovative drug research and development through various means, such as innovative drug investment funds [1] - The initiative aims to cultivate patient capital that supports innovative drugs [1]